• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于局部植物数据库的组合对接在结核分枝杆菌异柠檬酸裂解酶潜在抑制剂筛选中的应用。

Applications of Ensemble Docking in Potential Inhibitor Screening for Mycobacterium tuberculosis Isocitrate Lyase Using a Local Plant Database.

机构信息

Institute for Research in Molecular Medicine (INFORMM) , Universiti Sains Malaysia , 11800 Minden , Penang , Malaysia.

School of Data Science , Perdana University , 43400 Sri Kembangan , Selangor , Malaysia.

出版信息

J Chem Inf Model. 2019 May 28;59(5):2487-2495. doi: 10.1021/acs.jcim.8b00963. Epub 2019 Mar 14.

DOI:10.1021/acs.jcim.8b00963
PMID:30840452
Abstract

Isocitrate lyase (ICL) is a persistent factor for the survival of dormant stage Mycobacterium tuberculosis (MTB), thus a potential drug target for tuberculosis treatment. In this work, ensemble docking approach was used to screen for potential inhibitors of ICL. The ensemble conformations of ICL active site were obtained from molecular dynamics simulation on three dimer form systems, namely the apo ICL, ICL in complex with metabolites (glyoxylate and succinate), and ICL in complex with substrate (isocitrate). Together with the ensemble conformations and the X-ray crystal structures, 22 structures were used for the screening against Malaysian Natural Compound Database (NADI). The top 10 compounds for each ensemble conformation were selected. The number of compounds was then further narrowed down to 22 compounds that were within the Lipinski's Rule of Five for drug-likeliness and were also docked into more than one ensemble conformation. Theses 22 compounds were furthered evaluate using whole cell assay. Some compounds were not commercially available; therefore, plant crude extracts were used for the whole cell assay. Compared to itaconate (the known inhibitor of ICL), crude extracts from Manilkara zapota, Morinda citrifolia, Vitex negundo, and Momordica charantia showed some inhibition activity. The MIC/MBC value were 12.5/25, 12.5/25, 0.78/1.6, and 0.39/1.6 mg/mL, respectively. This work could serve as a preliminary study in order to narrow the scope for high throughput screening in the future.

摘要

异柠檬酸裂解酶(ICL)是休眠期结核分枝杆菌(MTB)存活的持久因素,因此是结核病治疗的潜在药物靶点。在这项工作中,使用集合对接方法筛选 ICL 的潜在抑制剂。通过对三个二聚体系统(即无配体 ICL、与代谢物(乙醛酸和琥珀酸)结合的 ICL 和与底物(异柠檬酸)结合的 ICL)的分子动力学模拟,获得了 ICL 活性位点的集合构象。结合集合构象和 X 射线晶体结构,对马来西亚天然化合物数据库(NADI)进行了 22 种结构的筛选。为每个集合构象选择了前 10 种化合物。然后,将化合物的数量进一步缩小到 22 种符合 Lipinski 五规则(药物似性)且结合到多个集合构象中的化合物。对这些 22 种化合物进行了全细胞测定进一步评估。由于某些化合物无法商业化获得,因此使用植物粗提物进行全细胞测定。与衣康酸(ICL 的已知抑制剂)相比,来自 Manilkara zapota、Morinda citrifolia、Vitex negundo 和 Momordica charantia 的粗提物显示出一些抑制活性。MIC/MBC 值分别为 12.5/25、12.5/25、0.78/1.6 和 0.39/1.6mg/mL。这项工作可以作为未来高通量筛选的初步研究,以缩小范围。

相似文献

1
Applications of Ensemble Docking in Potential Inhibitor Screening for Mycobacterium tuberculosis Isocitrate Lyase Using a Local Plant Database.基于局部植物数据库的组合对接在结核分枝杆菌异柠檬酸裂解酶潜在抑制剂筛选中的应用。
J Chem Inf Model. 2019 May 28;59(5):2487-2495. doi: 10.1021/acs.jcim.8b00963. Epub 2019 Mar 14.
2
Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.鉴定一种新型异柠檬酸裂解酶抑制剂作为针对活性和非复制性结核分枝杆菌的强效抗结核药物。
Tuberculosis (Edinb). 2016 Mar;97:38-46. doi: 10.1016/j.tube.2015.12.003. Epub 2016 Jan 6.
3
Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.基于结构的筛选和分子动力学模拟为潜在的结核分枝杆菌异柠檬酸裂解酶抑制剂提供了新型天然化合物。
J Biomol Struct Dyn. 2018 Jun;36(8):2045-2057. doi: 10.1080/07391102.2017.1341337. Epub 2017 Jun 26.
4
Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary.结核分枝杆菌和非结核分枝杆菌异柠檬酸裂解酶的潜在抑制剂:综述
Biomed Res Int. 2015;2015:895453. doi: 10.1155/2015/895453. Epub 2015 Jan 8.
5
Active Site Flexibility of Mycobacterium tuberculosis Isocitrate Lyase in Dimer Form.结核分枝杆菌二聚体形式异柠檬酸裂合酶的活性位点灵活性
J Chem Inf Model. 2017 Sep 25;57(9):2351-2357. doi: 10.1021/acs.jcim.7b00265. Epub 2017 Sep 1.
6
Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor.合成各种 3-硝基丙酰胺作为结核分枝杆菌异柠檬酸裂解酶抑制剂。
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5149-54. doi: 10.1016/j.bmcl.2011.07.062. Epub 2011 Jul 26.
7
Isocitrate lyase of Mycobacterium tuberculosis is inhibited by quercetin through binding at N-terminus.结核分枝杆菌异柠檬酸裂解酶通过与 N 端结合被槲皮素抑制。
Int J Biol Macromol. 2015;78:137-41. doi: 10.1016/j.ijbiomac.2015.04.005. Epub 2015 Apr 11.
8
Identification of mannich base as a novel inhibitor of Mycobacterium tuberculosis isocitrate by high-throughput screening.高通量筛选鉴定 Mannich 碱为结核分枝杆菌异柠檬酸的新型抑制剂。
Int J Biol Sci. 2011 Apr 7;7(3):376-82. doi: 10.7150/ijbs.7.376.
9
Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase.抗分枝杆菌植物化学成分筛选及其对结核分枝杆菌异柠檬酸裂解酶潜在抑制剂的研究。
Curr Top Med Chem. 2019;19(8):600-608. doi: 10.2174/1568026619666190304125603.
10
Heterogeneous multimeric structure of isocitrate lyase in complex with succinate and itaconate provides novel insights into its inhibitory mechanism.异柠檬酸裂解酶与琥珀酸和衣康酸复合物的异质多聚体结构为其抑制机制提供了新的见解。
PLoS One. 2021 May 5;16(5):e0251067. doi: 10.1371/journal.pone.0251067. eCollection 2021.

引用本文的文献

1
Advances in computational frameworks in the fight against TB: The way forward.抗击结核病计算框架的进展:前进之路。
Front Pharmacol. 2023 Apr 3;14:1152915. doi: 10.3389/fphar.2023.1152915. eCollection 2023.
2
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.结核分枝杆菌的致病机制:对新药研发的启示
Mol Biomed. 2022 Dec 22;3(1):48. doi: 10.1186/s43556-022-00106-y.
3
Discovery of a Novel Inhibitor Structure of Isocitrate Lyase.发现异柠檬酸裂解酶的新型抑制剂结构。
Molecules. 2022 Apr 11;27(8):2447. doi: 10.3390/molecules27082447.
4
Structure-based approaches for drug discovery against .针对……的基于结构的药物发现方法
Comput Struct Biotechnol J. 2021 Jun 24;19:3708-3719. doi: 10.1016/j.csbj.2021.06.034. eCollection 2021.
5
Itaconate is a covalent inhibitor of the isocitrate lyase.衣康酸是异柠檬酸裂解酶的共价抑制剂。
RSC Med Chem. 2020 Oct 19;12(1):57-61. doi: 10.1039/d0md00301h. eCollection 2021 Jan 1.
6
Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase.解析结核分枝杆菌异柠檬酸裂解酶的催化途径。
Sci Rep. 2020 Nov 3;10(1):18925. doi: 10.1038/s41598-020-75799-8.
7
In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors.马来植物中的积雪草苷和积雪草酸的计算机分析与细胞毒性研究作为潜在的 mTOR 抑制剂。
Molecules. 2020 Sep 2;25(17):3991. doi: 10.3390/molecules25173991.
8
Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.结核分枝杆菌去氢奎宁酸脱水酶 II 型抑制剂的一系列分子建模及新型配体的设计。
Mol Divers. 2021 Feb;25(1):1-12. doi: 10.1007/s11030-019-10020-1. Epub 2019 Dec 9.